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Abstract
Chagas disease is a neglected disease that remains a public health threat, particularly in
Latin America. The most important treatment options are nitroimidazole derivatives, such as
nifurtimox and benznidazole (BZN). Some studies suggest that for adults seropositive to T.
cruzi but without clinically evident chronic Chagas cardiomyopathy (CCC), a simple fixed-
dose scheme of BZN could be equivalent to a weight-adjusted dose. We compared the effi-
cacy and safety of a fixed dose of BZN with an adjusted dose for T. cruzi seropositive adults
without CCC. We used the Cochrane methods, and reported according to the PRISMA
statement. We included randomized controlled trials (RCTs) allocating participants to fixed
and/or adjusted doses of BZN for T. cruzi seropositive adults without CCC. We searched
(December 2019) Cochrane, MEDLINE, EMBASE, LILACS, Clinicaltrials.gov, and Interna-
tional Clinical Trials Registry Platform (ICTRP), and contacted Chagas experts. Selection,
data extraction, and risk of bias assessment, using the Cochrane tool, were performed inde-
pendently by pairs of reviewers. Discrepancies were solved by consensus within the team.
Primary outcomes were parasite-related outcomes and efficacy or patient-related safety
outcomes. We conducted a meta-analysis using RevMan 5.3 software and used GRADE
summary of finding tables to present the certainty of evidence by outcome. We identified
655 records through our search strategy and 10 studies (four of them ongoing) met our
inclusion criteria. We did not find any study directly comparing fixed vs adjusted doses of
BZN, however, some outcomes allowed subgroup comparisons between fixed and adjusted
doses of BZN against placebo. Moderate-certainty evidence suggests no important sub-
group differences for positive PCR at one year and for three safety outcomes (drug
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discontinuation, peripheral neuropathy, and mild rash). The same effect was observed for
any serious adverse events (low-certainty evidence). All subgroups showed similar effects
(I2 0% for all these subgroup comparisons but 32% for peripheral neuropathy), supporting
the equivalence of BZN schemes.
We conclude that there is no direct evidence comparing fixed and adjusted doses of
BZN. Based on low to very low certainty of evidence for critical clinical outcomes and moder-
ate certainty of evidence for important outcomes, fixed and adjusted doses may be equiva-
lent in terms of safety and efficacy. An individual patient data network meta-analysis could
better address this issue.
Author summary
Chagas disease is a major public health problem that requires, among other control inter-
ventions, an optimal trypanocidal therapy that achieves the best possible compliance to
cure active infection, mainly in children and young populations, women before they
become pregnant to prevent congenital transmission, and chronic populations who are
currently not being treated and with a risk of progression to cardiomyopathy. Some stud-
ies suggest that a simple fixed-dose scheme of benznidazole could be equivalent to the
dose adjusted by weight for the treatment of adults seropositive to T. cruzi without clini-
cally evident chronic Chagas cardiomyopathy. To confirm or reject this potential equiva-
lence of schemes, we conducted a rigorous systematic review and meta-analysis of
randomized controlled trials by reviewing and analyzing the totality of available literature
on the subject. Although we did not find direct evidence addressing this question, it
appears that an adjusted dose is probably equivalent in terms of important safety and effi-
cacy outcomes, while the effect on critical outcomes is uncertain. Since we did not find
any ongoing study comparing fixed versus adjusted doses of benznidazole, we are con-
ducting an individual patient data network meta-analysis to address this question.
Introduction
Chagas disease (CD), also known as human American trypanosomiasis, is a condition result-
ing from infection by the parasiteT. cruzi. Chagas disease remains a major public health prob-
lem; between five and 18 million people are currently infected and the disease is estimated to
cause more than 10,000 deaths annually[1]. Globally, the annual burden is $627.5 million in
health-care costs[2], and 232,000 to 806,170 disability-adjusted life years (DALYs)[3]. The
Latin American region bears most of the burden of Chagas disease, accounting for at least
206,000[2] to 662,000 DALYs lost[4]. A study investigating the economic value of a therapeutic
Chagas vaccine found that when administering standard of care benznidazole (BZN) to 1000
indeterminate patients, 148 discontinued treatment and 219 progressed to chronic disease,
resulting in 119 Chagas-related deaths and 2293 DALYs, costing $18.9 million in lifetime soci-
etal costs[5]. Population migration dynamics combined with the increased risk of mothers
infecting their unborn children and the increased risk of infection from blood or solid-organ
donations, means that CD has become a global problem[6]. The number of infected individu-
als has been estimated at 300,000 in the USA,[7] and 80,000 in Europe[8]. Primary acute T.
cruzi infection is seldom clinically evident, given its lack of defining features. CD is often
asymptomatic or resembles a common viral illness, although more serious outcomes such as
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myocarditis or meningoencephalitis are possible. During this period, T. cruzi trypomastigotes
are directly observable in the bloodstream. After this comes an indeterminate chronic phase,
during which T. cruzi lodges in organ tissue in amastigote form, inducing a specific immune
response. While most remain asymptomatic, 30–40% of patients progress to an advanced dis-
ease stage, usually years to decades after the initial infection. The advanced chronic phase fre-
quently involves damage to the conduction system of the heart and the myocardium, which
can result in heart failure and sudden death. In the Americas, myocarditis secondary to CD is
the most common form of nonischemic cardiomyopathy[9]. In other cases, CD produces gas-
trointestinal disorders (especially megaesophagus and megacolon), or disorders of the central
or peripheral nervous system, particularly in immunocompromised patients. Serology is used
to confirm a diagnosis of chronic T. cruzi infection and polymerase chain reaction (PCR) con-
tributes to that diagnosis. For years, host-based control was considered a difficult goal to
achieve and consequently, in the 1990s, public health authority efforts were focused on pri-
mary prevention, Triatoma infestans-based control, and control of blood donors to prevent
infection of individuals at risk[10]. In recent years, significant progress has been made in the
fight against triatomines, which, added to the controls implemented by blood banks, has dras-
tically reduced T. cruzi infections by vectors and transfusions. Interest in host-based control,
that is treating chronically infected individuals with trypanocidal therapy, has increased[11,
12]. Additionally, the focus on vector-based control has left the already infected population
without interventions that are potentially preventive of CCC[13]. Two nitroimidazolic deriva-
tives, BZN and nifurtimox, are the only approved trypanocidal options currently used, with no
important differences in their relative efficacy, adverse effects (AEs) and cost[14]. The usual
recommended dose of BZN is 5 to 7 mg/kg/day orally (5–10 mg/kg for children up to 12 years
old) divided into two or three times daily, for 60 days for adults. The most frequently reported
side effects are skin reactions and neuropathy, which commonly result in interruption of treat-
ment[15].
Recently, several studies[16–18] suggested that the use of a simpler fixed dose of BZN may
be equivalent to an adjusted dose in terms of effectiveness, simplifying its administration and
enhancing compliance. In order to compare the efficacy and safety of both schemes for T.
cruzi seropositive adults without CCC, we have systematically searched and extracted data
from eligible studies comparing relevant clinical, parasitological, and biochemical outcomes
for seropositive adults exposed to fixed and/or adjusted doses of BZN.
Methods
We conducted a systematic review and meta-analysis following Cochrane methods,[19] and
the PRISMA statement for reporting[20, 21]. The study protocol was registered in PROSPERO
(CRD42019120905).
Eligibility criteria
Randomized controlled trials (RCTs) allocating adults with asymptomatic chronic Chagas dis-
ease to fixed and/or adjusted doses BZN vs placebo or other trypanocidal treatments were
included. RCTs had to include people with chronic T. cruzi infection, diagnosed with positive
serology by at least two of the following techniques: ELISA, indirect hemagglutination (IHA),
or indirect immunofluorescence (IIF), mainly without clinically evident (i.e. symptomatic)
CCC. Important safety and efficacy outcomes, including proxies as positive serology or PCR,
any adverse events (AEs) and serious adverse events (SAEs) and critical patient (clinical)
related outcomes, such as all-cause mortality or significant progression of CCC, were
analyzed.
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Search strategy
We searched during December 2019 the following databases: Cochrane Database of Systematic
Reviews (CDSR), Cochrane Central Register of Controlled Trials (CENTRAL), Database of
Abstracts of Reviews of Effects (DARE), MEDLINE, EMBASE, LILACS, Clinicaltrials.gov, and
the WHO International Clinical Trials Registry Platform (ICTRP).
The basic search strategy included the following terms: (Chagas Disease [Mesh] OR Chagas
[tiab] OR Trypanosom�[tiab] OR Cruzi[tiab] OR T.Cruzi[tiab]) AND (Benznidazole[Supple-
mentary Concept] OR benznidazol�[tiab] OR Radanil[tiab] OR Rochagan[tiab] OR N-bencil-
2-acetamide[tiab]).
The search strategy was adapted to each database (See S1 Text).
No language limitations or publication date restrictions were applied. For studies with mul-
tiple publications, we decided how to best use the data on a case-by-case basis through discus-
sion with the principal investigators.
Additional searches included a Google search (the first 100 hits, in order of relevance, when
typing Chagas benznidazol), handsearching of reference lists of systematic reviews and eligible
studies retrieved with the electronic search, and verbal feedback from experts in the field.
Screening and data extraction
Selection, data extraction, and risk of bias assessment were performed independently by pairs
of reviewers from the research team. Discrepancies were solved by consensus within the team.
All the study selection phases were completed using COVIDENCE, a web-based platform
designed for the systematic review process. Authors of articles were contacted when necessary
to obtain missing or supplementary information.
A pre-designed general data extraction form was used after pilot testing.
We extracted the source of study report, study location and setting, population, disease defi-
nition of chronic T. cruzi infection, diagnostic tests used (number and type of laboratory tests
used), quality control measures, BZN and other treatment schedules, and follow-up measures.
Risk of bias (quality) assessment
Pairs of independent reviewers assessed the risk of bias (quality) using the Cochrane Collabo-
ration tool[22]. See details in S2 Text. Discrepancies were solved by consensus within the
team.
Data synthesis
We conducted a traditional aggregate meta-analysis by using the Review Manager 5.3 software
package[23]. Pooled effect estimates and their 95% confidence intervals (CI), when appropri-
ate, were generated using a random-effects model. We reported risk ratios (RR) for dichoto-
mous outcomes (e.g. positive serology after treatment), the Peto odds ratio (OR) for very
infrequent outcomes, and the mean difference (MD) for continuous data such as antibody
titers. For dichotomous data, we used the Mantel-Haenszel method, and for continuous data,
we used the inverse variance method.
We described statistical heterogeneity of intervention effects by calculating the I2 statistic
and we interpreted 0–30% as not important, 30–60% as moderate heterogeneity, and more
than 60% as substantial heterogeneity. Since we assume that clinical heterogeneity is very likely
to impact our review results, given the nature of the interventions included, we primarily
reported the random-effects model results, however, we also applied the fixed effect model as a
sensitivity analysis. We calculated all overall effects using inverse variance methods.
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Where necessary, we contacted the corresponding authors of included studies up to three
times to supply any unreported data.
We planned subgroup analyses (see protocol) by age of participants at time of treatment
(young adults vs. older population), type of serological test (conventional serology vs. non-
conventional serology), time of treatment and testing (less than ten years vs. equal or more
than ten years), and region where the patient was infected (Central vs. South America). We
expected, ex ante, to find an earlier and higher rate of seroconversion in Central America due
to the presence of different parasite lineages, i.e., T. cruzi type I predominating in Central
America and T. cruzi type Non-I (II, V and VI) in South America.
We planned to undertake sensitivity analyses to determine the effect of restricting the analy-
sis to only: (a) studies with low risk of selection bias (associated with sequence generation or
allocation concealment), (b) studies with low risk of performance bias (associated with issues
of blinding), and (c) studies with low risk of attrition bias (associated with completeness of
data).
Finally, we used the GRADE profiler software package[24–26] in order to assign a level of
evidence around the data extracted and to generate pooled estimates and their CIs, and to pro-
duce summary of findings tables.
Results
We identified 803 records through the database search and one additional record by contact-
ing authors. After removing duplicates, 655 records were screened by title and abstract and 22
by full-text. Ultimately, 10 studies (four of them ongoing studies) met our inclusion criteria
(Fig 1).
Included and ongoing studies
We included six completed RCTs[16, 17, 27–30] and identified four ongoing studies[18, 31–
33] that met our inclusion criteria(See Table 1 and S3 Text). These studies directly compared
fixed vs adjusted doses of BZN. Of the included studies, four were already published[17, 28–
30] and details of the remaining two[16, 27] were obtained by personal communication with
the authors.
Patients were recruited from Argentina, Bolivia, and Spain (two studies each), and from
Brazil, Chile, Mexico, and Guatemala (one study each). Three studies used an adjusted dose
[27, 28, 30] and three fixed doses[16, 17, 29]. One study was started before 1997 and used serol-
ogy and xenodiagnosis[28], those that recruited patients from 1999 to 2018 used PCR for para-
sitological outcomes. Only one study provided long-term clinical outcomes, including
cardiovascular mortality and progression of cardiomyopathy, but for comparison reasons we
used a shorter follow-up period as in the majority of studies for non-clinical outcomes[27].
The mean sample size was 330 (minimum 77, maximum 910).
Although the ongoing studies are not included in the evidence synthesis, we have described
them in detail (see Table 1) in order to explain how they might be able to answer our main
question in the near future. Patients in these studies are being recruited from Argentina,
Bolivia, Brazil, Colombia, and Spain. Only one of them will use an adjusted dose[31] and all of
them will use PCR to detect presence of parasites.
Excluded studies
We excluded 12 studies, three of these were duplicate records. The reasons for excluding the
other nine[34–42] are described in S3 Text; seven of these were excluded due to a wrong study
design.
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Risk of bias in included studies
Only one study was considered of unclear risk of bias for the randomization domains[17]; two
studies were considered of high risk for blinding assessment[17, 29] and one study for blinding
of participants and personnel[29]; and two studies presented unclear risk for selective report-
ing[28, 43](see Fig 2, and in S4 Text).
Fig 1. Study flow diagram. O: Objective outcomes; S: Subjective outcomes.
https://doi.org/10.1371/journal.pntd.0008529.g001
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Effects of interventions
In considering the main question of this review, we focused the results on comparisons that
included both fixed and adjusted doses of BZN, for which we presented GRADE summary of
finding tables.
Benznidazole fixed vs adjusted dose
There was no head-to-head study exploring this comparison but, based on inferences from
indirect comparisons of BZN-treated patients versus placebo, using PCR at one year and safety
outcomes (see BZN versus placebo below), we did not observe important differences between
fixed and adjusted doses (see Table 2). The certainty of evidence for these outcomes was down-
graded one or two levels because of indirectness.
Benznidazole at different fixed doses
We identified the unpublished study BENDITA[16], which did not find important differences
in positive PCR between BZN 150 vs 300 for 8 weeks (RR 1.00; IC95% 0.24–4.18), 150 vs 300
for 4 weeks (RR 1.20; IC95% 0.27–5.25), and 150 vs 300 for 2 weeks (RR 0.86; IC95% 0.21,
3.47). The authors also found no differences in AEs for the same comparisons: RR 0.88
(IC95% 0.56, 1.36), RR 1.05 (IC95% 0.65, 1.69), and RR 0.86 (IC 95% 0.49, 1.50) respectively.
There were very few serious adverse events (SAEs) and drug discontinuations due to AEs, and
no evidence of differences between groups. However, the study design was unpowered to
detect differences between arms.
Table 1. Main characteristics of included and ongoing studies.
Short title PI Start/end
years
N Countries Study status Benznidazole
dose
Comparison Outcomes
Rodrigues C. 1997[28] Rodrigues
Coura, J.




E1224[30] Torrico, F. 2011/2 231 Bolivia Completed Adjusted E1224 / Placebo PCR
CHAGASAZOL [29] Molina, C. 2010/1 79 Spain Completed Fixed Posaconazole PCR
STOP-CHAGAS[17] Morillo, I. 2011/3 120 Argentina, Chile,
México, Guatemala,
Spain
Completed Fixed Posaconazole /
Placebo
PCR
BENDITA[16] Torrico, F. 2017/8 210 Bolivia Completed
Unpublished
Fixed E1224 / Placebo PCR













Villar, JC. 2015/ 500 Colombia Ongoing Adjusted Nifurtimox/
Placebo
PCR
MULTIBENZ [18] Molina, I. 2017/ 240 Spain, Brazil Argentina,
Colombia
Ongoing Fixed Benznidazole 150/
400 mg
PCR
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Benznidazole versus placebo
Efficacy was determined by positive serology, positive PCR, positive xenodiagnosis, mean
reduction of antibody titer, mean reduction in PCR load, and clinical outcomes at the end of
follow-up.
Positive serology: we identified one published study[28] without differences between
groups (RR 1.00; IC95% 0.93–1.08) and one study[27] that favors treatment with BZN (RR
0.88; IC95% 0.84–0.93), both using an adjusted dose. The pooled RR was 0.94 (IC95% 0.82–
1.08) and the certainty of evidence was considered low (see Fig 3). The TRAENA study[27]
showed a RR of 0.65 (IC95% 0.58–0.63) at six years.
Positive PCR: both the fixed[17] and adjusted doses[16, 30] of BZN were effective at reduc-
ing positive PCR at one year against placebo (RR 0.20; IC95% 0.10–0.30) without differences
in subgroups between the fixed dose of 300 mg/day for 14 to 56 days and the adjusted dose: RR
0.12 (IC95% 0.04–0.36) and RR 0.19 (IC95% 0.10–0.37), respectively. The significance of the
test for subgroup differences was Chi2 = 0.56, df = 1 (P = 0.45), I2 = 0% (see Fig 4 and Table 3).
Positive xenodiagnosis: only one study provided data about an adjusted dose[28], favoring
BZN (RR 0.12, 95% CI 0.04 to 0.36; participants = 60; studies = 1).
Mean reduction in PCR load (GMT one year): Two studies provided data about an adjusted
dose[27, 30] and showed no significant difference: (MD -0.48; 95% CI -1.19, 0.23, partici-
pants = 480; studies = 2).
Fig 2. Risk of bias item for each included study. A) Random sequence generation (selection bias), (B) allocation
concealment (selection bias), (C) blinding of participants and personnel (performance bias), (D) blinding of outcome
assessment (detection bias), (E) incomplete outcome data (attrition bias), (F) selective reporting (reporting bias), (G)
other bias O: Objective outcomes, S: subjective outcomes.
https://doi.org/10.1371/journal.pntd.0008529.g002
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Mean reduction of antibody titer at one year: only one study (92 participants) provided
data about an adjusted dose[30] and showed no difference with placebo (Conventional ELISA:
MD 0.01, 95% CI -0.17 to 0.19 and AT CL−ELISA: MD 0.01, 95% CI -0.07 to 0.09) except
when using the geometric mean measured by AT CL−ELISA (MD -0.57, 95% CI -1.08 to
-0.06).
Table 2. Summary of findings: Benznidazole fixed vs adjusted dose.



































Any serious adverse events Based only in the surrogate outcome drug discontinuation, differences between groups on





Refer to text for benznidazole versus placebo: Efficacy (PCR at one year�) and Safety#
1Downgraded one level due to serious indirectness, since these are inferences from subgroup analysis of comparisons between BZN and placebo.
2Downgraded two levels due to due to very serious indirectness (important uncertainty between the surrogate outcome + PCR and the critical outcomes cardiovascular
mortality and progression of cardiomyopathy) and methodological limitations to answering this question.
3Downgraded one level due to serious indirectness, since there is uncertainty between surrogate outcome drug discontinuation and SAEs.
https://doi.org/10.1371/journal.pntd.0008529.t002
Fig 3. Positive serology at one year. A) Random sequence generation (selection bias), (B) allocation concealment (selection bias), (C) blinding of
participants and personnel (performance bias), (D) blinding of outcome assessment (detection bias), (E) incomplete outcome data (attrition bias), (F)
selective reporting (reporting bias), (G) other bias.
https://doi.org/10.1371/journal.pntd.0008529.g003
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Clinical outcomes at the end of follow-up: one long-term study (n = 713) that used an
adjusted dose of BZN vs. placebo provided data about these outcomes,[27] and showed a RR
of 0.89 (95% CI 0.62 to 1.26) for progression of cardiomyopathy, RR 1.18, (95% CI 0.40 to
3.49) for cardiovascular mortality and RR 0.38 (95% CI 0.10 to 1.42) for pacemaker implanta-
tion, implantable cardioverters or severe arrhythmia with hemodynamic unbalance, and car-
diac failure.
As expected, the frequency of AEs is higher with BZN (see Supporting Information. Rev-
Man, and Raw and analysis data). Only three outcomes presented studies that used fixed or
adjusted dose against placebo: drug discontinuation, peripheral neuropathy (considered
SAEs), and mild rash (considered non-serious AEs).
Drug discontinuation: both the fixed and adjusted doses showed more drug discontinua-
tion than placebo and we found no subgroup difference: Test for subgroup differences: Chi2 =
0.12, df = 1 (P = 0.73), I2 = 0% 9 (see Fig 5 and Table 3).
Fig 4. Positive PCR at one year. A) Random sequence generation (selection bias), (B) allocation concealment (selection bias), (C) blinding of
participants and personnel (performance bias), (D) blinding of outcome assessment (detection bias), (E) incomplete outcome data (attrition bias), (F)
selective reporting (reporting bias), (G) other bias.
https://doi.org/10.1371/journal.pntd.0008529.g004
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Table 3. Summary of findings: Benznidazole versus placebo.
















- Fixed dose 300 mg/day for 14 to 56
days

























































































Fig 5. Drug discontinuation. A) Random sequence generation (selection bias), (B) allocation concealment (selection bias), (C) blinding of participants
and personnel (performance bias), (D) blinding of outcome assessment (detection bias), (E) incomplete outcome data (attrition bias), (F) selective
reporting (reporting bias), (G) other bias.
https://doi.org/10.1371/journal.pntd.0008529.g005
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Peripheral neuropathy: we found no subgroup differences: Test for subgroup differences:
Chi2 = 1.50, df = 1 (P = 0.22), I2 = 33.2%. See Fig 6 and Table 3.
Mild rash: we found no subgroup difference: Test for subgroup differences: Chi2 = 0.14,
df = 1 (P = 0.93), I2 = 0%) (see Fig 7 and Table 3).
Benznidazole versus posaconazole
We identified two studies that used fixed-dose BZN versus posaconazole[17, 29] and consider-
ing the longest follow-up period, both favored BZN (RR 0.24, 95% CI 0.06 to 0.93;
Fig 6. Peripheral neuropathy. A) Random sequence generation (selection bias), (B) allocation concealment (selection bias), (C) blinding of
participants and personnel (performance bias), (D) blinding of outcome assessment (detection bias), (E) incomplete outcome data (attrition bias), (F)
selective reporting (reporting bias), (G) other bias.
https://doi.org/10.1371/journal.pntd.0008529.g006
Fig 7. Mild rash. (1) Bendita 20117 (Maculo-papular rash + papular rash + erythema. A) Random sequence generation (selection bias), (B) allocation
concealment (selection bias), (C) blinding of participants and personnel (performance bias), (D) blinding of outcome assessment (detection bias), (E)
incomplete outcome data (attrition bias), (F) selective reporting (reporting bias), (G) other bias.
https://doi.org/10.1371/journal.pntd.0008529.g007
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participants = 112; studies = 2; I2 = 81%). Test for subgroup differences by follow-up: Chi2 =
4.17, df = 1 (P = 0.04), I2 = 76.0% due to higher effect in Morillo 2017 (follow-up 360 days)[17]
than in Molina 2014 (follow-up 280 days)[29].
Subgroup analysis and sensitivity analysis
Due to the low number of included studies it was not possible to conduct the planned sub-
group analyses, except for the fixed and adjusted doses related to the question of our review.
For the same reason, it was not possible to conduct the planned sensitivity analyses, restrict-
ing the analysis to only studies with low risk of selection bias (associated with sequence genera-
tion or allocation concealment). Morillo et al.[17] (unclear risk of bias for this domain) was
the only fixed-dose study included in the subgroup comparison between fixed and adjusted
doses of BZN.
All studies included in the subgroup comparison between fixed and adjusted doses of BZN
were of low risk of performance bias (associated with issues of blinding) and low risk of attri-
tion bias (associated with completeness of data) except for TRAENA[27]. We found consis-
tency of results applying both fixed-effect and random-effects models and also using OR and
RD.
Discussion
The only drugs with proven efficacy against Chagas disease are BZN and nifurtimox. BZN is
used in children and adults and is registered for use in adjusted-dose schemes. However, some
investigators have proposed the more flexible use of fixed dosing regardless of body weight.
After searching all completed and ongoing RCTs involving BZN at any dose, we found no
direct comparison between fixed and adjusted doses of BZN.
We only found one efficacy outcome (positive PCR) and three safety outcomes (drug dis-
continuation, peripheral neuropathy, and mild rash) that allowed the subgroup comparisons
between fixed and adjusted doses of BZN [16, 17, 27, 28, 30] The low or null I2 for all these sub-
group comparisons suggest no important clinical, methodological, or statistical differences in
the observed effects by type of dosing. Since these are inferences from indirect comparisons of
BZN-treated patients versus placebo, the certainty of evidence for these outcomes was conse-
quently downgraded one or two levels because of indirectness.
We found a high certainty of evidence for the direct comparisons between BZN versus pla-
cebo for the efficacy outcome (positive PCR) and for the three safety outcomes (drug discon-
tinuation, peripheral neuropathy and mild rash). However, these four outcomes are
considered as moderate certainty of the evidence for the comparison fixed vs adjusted dose of
benznidazole after downgrading one level due to indirectness (indirect comparisons). The cer-
tainty of the evidence was considered to be very low for cardiovascular mortality and progres-
sion of cardiomyopathy due to significant uncertainty between the surrogate positive PCR
outcome and these critical outcomes. The certainty of the evidence was considered low for any
SAE due to uncertainty between this outcome and the surrogate outcome drug discontinua-
tion. See Table 2 (based on indirect comparisons) and Table 3 (for direct comparisons between
BZN and placebo by type of dose).
We found six related systematic reviews that showed similar results in terms of the effect of
interventions against placebo, however, none of them addressed our question concerning the
comparison of fixed and adjusted doses of BZN [38, 39, 42, 44–46]. Observational studies sug-
gest that treatment could be better that no treatment even in the early phases of CCC[46].
Unfortunately, non-RCT studies used adjusted doses of BZN, not allowing the assessment of
subgroup analysis by BZN scheme. Unlike other reviews, we only included RCTs to reduce the
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risk of bias, but, as was the case for the previous studies, we had to deal with differences in the
populations studied, follow-up periods, diagnostic techniques, and sample size.
Demonstration that a fixed dose of BZN has a similar profile in relation to safety and effi-
cacy would allow a review of the current guidelines and the recommendation of fixed doses,
eliminating one barrier to treatment management, and improving compliance by patients and
health workers.
The strengths of this systematic review of RCTs include the registration of its protocol, the
complete literature search, the rigorous Cochrane methods used, the participation of most
principal investigators of the RCTs included, and the inclusion of valuable unpublished data.
All these factors make our study the most complete evidence synthesis currently available that
addresses the comparative efficacy and safety of adjusted-dose BZN for T. cruzi seropositive
adults mainly without CCC.
The population included in the trials is representative of the population of adults with
chronic Chagas disease without cardiomyopathy, however important limitations need to be
mentioned. First of all, the absence of direct comparisons between fixed and adjusted doses of
BNZ, and the assessments of critical outcomes should be noticed. Additionally, the paucity of
studies prevented us from performing our planned subgroup and sensitivity analyses. The
unpublished TRAENA study[27] was the only one that succeeded in assessing long-term clini-
cal outcomes.
Individual patient data (IPD) meta-analysis could address these issues, for example by
including cumulative dose assessments. Moreover, network IPD meta-analysis could formally
enhance indirect comparisons.
Conclusion
Based on a low to very low certainty of evidence for critical clinical outcomes and a moderate
certainty of evidence for important outcomes, fixed and adjusted doses of BZN might be con-
sidered equivalent in terms of efficacy and safety.
An IPD meta-analysis would allow us to conduct the planned subgroup analysis and meta-
regressions, but given the absence of a direct comparison between fixed and adjusted doses of
BZN, the only approach to gain in certainty of evidence to address the objective of the review
would be an IPD network-meta-analysis—an approach which our research group is currently
following.
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